Introduction
============

Optic neuropathy, a common visual impairment, can be caused by genetic defects, toxic factors, and ocular or brain diseases \[[@r1]-[@r3]\]. Genetic defects may occur in nuclear genome or mitochondrial DNA (mtDNA) \[[@r4]-[@r6]\]. Mutations in mtDNA are known to cause Leber hereditary optic neuropathy (LHON, MIM [535000](http://omim.org/entry/535000)) \[[@r7]\]. At least eight loci (OPA1 to OPA8) have been mapped to the nuclear genome in association with optic atrophy, in which three causative genes have been identified, including the optic atrophy 1 (*OPA1*, OMIM [605290](http://omim.org/entry/605290)) gene, the optic atrophy 3 (*OPA3*, OMIM [606580](http://omim.org/entry/606580)) gene, and the transmembrane protein 126A (*TMEM126A*, OMIM [612988](http://omim.org/entry/612988)) gene \[[@r1]\].

Dominant optic atrophy (DOA, MIM [165500](http://omim.org/entry/165500)) is the most common form of hereditary optic neuropathy resulting from mutations in nuclear genome, with a prevalence of 1 in 50,000 overall \[[@r8]\] and as high as 1 in 35,000 in the north of England \[[@r9]\], similar to the frequency of LHON (1 in 25,000 to 1 in 50,000) as reported in Caucasians \[[@r1],[@r10]\]. DOA typically presents as painless and slowly progressive visual loss, occurring insidiously with a mean age of onset at 6--10 years of age \[[@r1],[@r11]\]. DOA exhibits marked inter- and intrafamilial variable phenotypes \[[@r9],[@r12],[@r13]\]; for instance, about 25% of patients were found to have optic atrophy with fundus examination but without a complaint of visual deterioration \[[@r11],[@r14]\].

Of the three nuclear genes known to cause optic neuropathy when mutated, mutations in *OPA3* and *TMEM126A* are extremely rare. *OPA3* mutations result in optic atrophy associated with cataract \[[@r15],[@r16]\], while *TMEM126A* mutations are responsible for an autosomal recessive form of optic atrophy \[[@r17],[@r18]\]. Mutations in *OPA1* account for the majority (60%--70%) of patients with DOA \[[@r19]\]. Thus far, at least 230 pathogenic mutations have been identified in *OPA1* \[[@r20]\]. However, extremely variable phenotypes of DOA hindered the diagnosis and, therefore, the clinical test of *OPA1* mutational screening. Until now, the genotype-phenotype correlations of *OPA1* mutations with DOA were elusive \[[@r21],[@r22]\]. Recently, analysis of *OPA1* in some large case series of hereditary optic neuropathy in Caucasians suggested that scanning the most frequently mutated exons might be a good strategy for identifying *OPA1* mutations \[[@r21],[@r23]\]. Although exon 27, exon 8, and exon 15 may be mutational hot spots in Caucasians \[[@r21]\], the frequency of *OPA1* mutation in Chinese patients has not been evaluated. Only a few Chinese families with DOA have been reported to be associated with *OPA1* mutations \[[@r24]-[@r27]\], not to mention the mutational hot spots. In this study, Sanger sequencing was used to detect the mutation of *OPA1* in 193 Chinese families with suspected hereditary optic neuropathy, in which the three common LHON-associated primary mutations of mtDNA had been excluded with prior screening.

Methods
=======

Patients
--------

Probands with suspected hereditary optic neuropathy from 193 unrelated families were examined at the Pediatric and Genetic Clinic in Zhongshan Ophthalmic Center. The criteria for participating in this study were as follows: (1) reduced visual acuity not related to refractive error or ocular media; (2) optic atrophy revealed with fundus examination; (3) exclusion of optic atrophy with known causes; and (4) absence of the three common primary LHON-associated mutations in mtDNA, which was confirmed based on methods described in our previous study \[[@r28]\]. All probands were assessed by experienced ophthalmologists or neuro-ophthalmologists. Informed consent conforming to the tenets of the Declaration of Helsinki and the Guidance of Sample Collection of Human Genetic Diseases (863-Plan) by the Ministry of Public Health of China was obtained from the participants or their guardians before the study. For the probands from the 193 families, 155 were sporadic cases, and 38 had a family history of hereditary optic neuropathy; 132 were male, and 61 were female.

Mutation screening
------------------

Genomic DNA from the proband of each family was prepared from peripheral blood leukocytes as previously described \[[@r23]\]. All the coding exons and exon-intron junctions of *OPA1* (references from NCBI: [NC_000003.11](http://www.ncbi.nlm.nih.gov/nuccore/NC_000003.11) for gDNA, [NM_015560.1](http://www.ncbi.nlm.nih.gov/nuccore/NM_015560.1) for mRNA, and [NP_056375.2](http://www.ncbi.nlm.nih.gov/nuccore/NP_056375.2) for protein) were amplified with PCR using 30 primer sets ([Table 1](#t1){ref-type="table"}). The primer pairs were designed to cover at least 80 bp of each exon-intron junction, aiming to detect most of the known intronic mutations. PCR reaction was performed in 20 μl volumes containing 80 ng genomic DNA. Touchdown PCR was performed, which consisted of a denaturizing step at 95 °C for 5 min and annealing temperature decreased by 2 °C after the first 5 cycles and the second 5 cycles, and then down to the optimal annealing temperature (listed in [Table 1](#t1){ref-type="table"}), and a final extension at 72 °C for 5 min. Sequences of the amplicons were determined with BigDye Terminator cycle sequencing kit v3.1 and an ABI3130 Genetic Analyzer (Applied Biosystems, Foster City, CA). Sequences from patients and the *OPA1* reference sequence ([NM_015560.1](http://www.ncbi.nlm.nih.gov/nuccore/NM_015560.1)) were compared using SeqMan II software (Lasergene 8.0, DNASTAR, Madison, WI). All variations were confirmed with bidirectional sequencing, and novel mutations were then evaluated in 384 chromosomes of 192 normal individuals. The effect of a novel missense mutation on the encoded protein was predicted with the Blosum62 Table \[[@r29]\] as well as [PolyPhen-2](http://genetics.bwh.harvard.edu/pph2/) \[[@r30]\] and the [SIFT](http://sift.jcvi.org/) online tool \[[@r31]\]. Splice site mutations were predicted with the [Splice Site Prediction by Neural Network](http://www.fruitfly.org/seq_tools/splice.html) \[[@r32]\]. In addition, the degree of evolutionary conservation at amino acid positions altered by novel *OPA1* mutations was analyzed using the MegAlign program of the Lasergene package. Segregation analyses of mutations were performed on patients with available family members.

###### Primers used to amplify the genomic fragments of *OPA1*.

  Fragment      Forward primer (5′-3′)           Reverse primer (5′-3′)         Product length (bp)   Annealing temperature
  ------------- -------------------------------- ------------------------------ --------------------- -----------------------
  Exon 1        CCTCGGCCGCGGCTCTGTGC             GGGCTCCTGTCATTCTGGGTCCTCAAG    327                   65 °C
  Exon 2        TTTGCACCACATTTTCCTCATCT          GGCATCTTCCTATTAGCATCATTA       743                   60 °C
  Exon 3        GGGCAAAATTATGAAACCT              TAAAATTATGGGCTACTGG            523                   57 °C
  Exon 4        ACTGCCTGGGCTGGAAC                GGAACTGTCATTTTACTGGGC          507                   65 °C
  Exon 4b       GCCCTATCGTAATATGAAATCTGAG        GCATAAGCAGCATTATAAATTTGG       257                   60 °C
  Exon 5        AGGCGATTTGATTCTTTGA              ACTTGGATGTTTTTGTATTTG          320                   55 °C
  Exon 5b       AACCATCCCTCCCTAGCTTACATCT        GGCTTTACCTATACTACCCACTCCAG     396                   65 °C
  Exon 6        CTTTCATAAGAAATGACTAGAATAGCAACA   TGGGCATAAGATTCACTCAAAATAGG     560                   57 °C
  Exon 7        ATGTGAGTAGCAAGGAATTTTCCAAGTG     CCTCCAAGCACATTAGGTTAGAAAGAAA   484                   65 °C
  Exon 8        CTAAATAAACTGAATGAGAAATGGAC       ACATTACTTGGAACATGTAAGATTAC     446                   60 °C
  Exon 9        GTTTTGCTGTTCCTATTTTCAATGTGCA     GCCTCCTGGCTGTGCCTTCTACTGATTT   464                   65 °C
  Exon 10--11   CCCAGCAGTAGTGTGAAGGG             AAAACAATGCTAAAGTTTGGGG         716                   60 °C
  Exon 12--13   TGTGAGCGTCTTATCTGAATGGA          AATGAATACGAAGAGAAGGCAAAAA      506                   60 °C
  Exon 14       TTGCTATAATGTAGACACAGGGG          CCATGTACCATTTCCTTTTGTG         395                   60 °C
  Exon 15--16   TCATTCCGGGTTTTCGATAC             AAACTGCTCTCAATTCTGCC           662                   65 °C
  Exon 17       GCTACCGTATTGGAATGTTTTCCTCCTC     AAATGTTCTCATCTGTTTGAACTCTGCA   525                   65 °C
  Exon 18       GGGTCATAGGCGCACTCTC              TCTCAGAAAACACTTTCAACACTTG      425                   57 °C
  Exon 19       CCCAAATTCAGCCTAGTCAAAAA          GAGCCAAGGCAACAATAAATCAC        293                   65 °C
  Exon 20       GCTGGAGTGGAAGAACAAAGACAAA        CCCAAAACAGAGATGAGGAATAAAGAA    616                   65 °C
  Exon 21       CCATATCTGTCCCCAGCAAC             GCAACAGGTGATTTTAGAAGGG         541                   65 °C
  Exon 22       TAACAAATAAGCAGGCAAGTAAAAGAAG     CATTGGTTTTAGTAGTTACAAAGCAGTT   464                   60 °C
  Exon 23       ATGTGGGTTTTTTCCTTTA              GCATGTTTCATCTCTTGTC            448                   57 °C
  Exon 24       TGATTAAGCTTGTGTTATCTTTTATGC      CGTGACAAAAGTCAAATTAAGCAC       372                   60 °C
  Exon 25       CCTACCCTGTCTACTCCACAAG           TTTCCCCAGATGATCAAAGG           523                   60 °C
  Exon 26       TTAAGCTTAGGACATATCTACTGGTTC      TGGGAAGTATTTTGGCATCC           291                   60 °C
  Exon 27       TTTTGGGAAATCTGCACTTC             TCTGACCTTGTTTTCCACCC           533                   60 °C
  Exon 28       TTGGGTAAAAGGTGGTATGGTGAG         CAAGCAGGATGTAAATGAAGCAGAA      309                   65 °C

Results
=======

Optic atrophy 1 mutations
-------------------------

Upon complete sequencing analysis of *OPA1* coding exons and adjacent intronic regions, 11 heterozygous mutations in *OPA1* ([Table 2](#t2){ref-type="table"}, [Figure 1](#f1){ref-type="fig"}) were detected in 12 of 193 (6.2%) families, among which eight were novel and three were known. These mutations consisted of three nonsense mutations, two splice site mutations, three deletions, two missense mutations, and one small insertion. The c.2708_2711del mutation in exon 27 was present in three of the 12 probands (25%). In addition, three mutations were found in a fragment less than 10 bp around the 5′ end of exon 10. Of the 12 cases, nine were sporadic cases (9/155, 5.8%), and three had a family history (3/38, 8.0%). The eight novel mutations were predicted to be pathogenic and not detected in 384 control chromosomes. Polymorphisms detected in *OPA1* are listed in [Table 3](#t3){ref-type="table"}.

###### *OPA1* mutations identified in the 12 Chinese families with optic atrophy.

  OPA1        Patient ID               Nucleotide change   Amino acid change   Status   Conser vation   Computational prediction   Allele frequency in   Reported                   
  ----------- ------------------------ ------------------- ------------------- -------- --------------- -------------------------- --------------------- ---------- ------- ------- ----------------------------
  exon 2      le1608                   c.49_50insGG        p.L17fs             Hetero   \-              \-                         \-                    \-         1/386   0/384   This study
  exon 2      le2028                   c.190_194del        p.S64fs             Hetero   \-              \-                         \-                    \-         1/386   0/384   This study
  intron 9    le2146                   c.985--1G\>A        Splicing defect     Hetero   \-              \-                         \-                    \-         1/386   NA      Delettre et al. \[[@r40]\]
  exon 10     le1524                   c.989C\>G           p.T330S             Hetero   Yes             5\>1                       PrD                   D          1/386   0/384   This study
  exon 10     le1656                   c.991_992del        p.L331fs            Hetero   \-              \-                         \-                    \-         1/386   0/384   This study
  exon 11     le2028                   c.1129G\>A          p.V377I             Hetero   Yes             4\>3                       PrD                   T          1/386   0/384   This study
  exon 21     le1599                   c.2119G\>T          p.E707\*            Hetero   \-              \-                         \-                    \-         1/386   0/384   This study
  exon 24     le1432                   c.2389A\>T          p.K797\*            Hetero   \-              \-                         \-                    \-         1/386   0/384   This study
  exon 24     le1601                   c.2470C\>T          p.R824\*            Hetero   \-              \-                         \-                    \-         1/386   NA      Ferre et al. \[[@r21]\]
  intron 25   le1574                   c.2614--2A\>G       Splicing defect     Hetero   \-              \-                         SSA                   \-         1/386   0/384   This study
  exon 27     le1411, le1434, le2062   c.2708_2711del      p.V903fs            Hetero   \-              \-                         \-                    \-         3/386   NA      Ferre et al. \[[@r21]\]

The proband le2028 is compound heterozygous for two *OPA1* mutations, a frameshift deletion and a missense mutation ([Figure 2](#f2){ref-type="fig"}). Abbreviations: Hetero, Heterozygous; PrD, probably damaging; SSA, splicing site abolished; D, damaging; T, tolerated; NA, not analyzed.

![Sequence chromatograms. The 11 sequence changes detected in the probands with dominant optic atrophy are shown (left column) compared with corresponding normal sequences (right column). The mutational sites are indicated with an arrow, and the amino acid codes are depicted with a line.](mv-v19-292-f1){#f1}

###### Polymorphisms detected in the study.

  Nucleotide change           Amino acid change   Status        Conser- vation   Computational prediction   Allele frequency in cases   Reported or SNP ID             
  --------------------------- ------------------- ------------- ---------------- -------------------------- --------------------------- -------------------- --------- ----------------------------------------------------------------------------------
  c.43C\>A                    p.Q15K              Hetero        No               5\>1                       B                           T                    1/386     [rs75414918](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=75414918)
  c.321G\>A                   p.(S107=)           Hetero        NA               \-                         NC                          \-                   1/386     [rs117888848](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=117888848)
  c.473G\>A                   p.S158N             Hetero/homo   No               4\>1                       B                           T                    125/386   [rs7624750](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=7624750)
  c.557--19T\>C               \-                  Hetero/homo   NA               \-                         NC                          \-                   109/386   [rs3772393](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3772393)
  c.575C\>T                   p.A192V             Hetero        Yes              4\>0                       B                           T                    9/386     [rs34307082](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=34307082)
  c.624+13G\>C                \-                  Hetero        NA               \-                         NC                          \-                   3/386     this study
  c.625--4T\>A                \-                  Hetero        NA               \-                         NC                          \-                   1/386     this study
  c.870+4T\>C                 \-                  Hetero/homo   NA               \-                         NC                          \-                   12/386    Liu Y et al. \[[@r41],[@r42]\]
  c.870+32T\>C                \-                  Hetero/homo   NA               \-                         NC                          \-                   105/386   Liu Y et al. \[[@r41],[@r42]\]
  c.871--9T\>A                \-                  Hetero        NA               \-                         NC                          \-                   1/386     this study
  c.1177A\>C                  p.(R393=)           Hetero        NA               \-                         NC                          \-                   1/386     [rs149752576](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=149752576)
  c.1608A\>C                  p.(A536=)           Hetero        NA               \-                         NC                          \-                   11/386    [rs78767626](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=78767626)
  c.1770+16T\>G               \-                  Hetero/homo   NA               \-                         NC                          \-                   27/386    [rs9831772](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=9831772)
  c.1884A\>G                  p.(V628=)           Hetero        NA               \-                         NC                          \-                   9/386     [rs73069703](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=73069703)
  c.1923G\>A                  p.(A641=)           Hetero        NA               \-                         NC                          \-                   3/386     [rs138114609](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=138114609)
  c.2109T\>C                  p.(A703=)           Hetero/homo   NA               \-                         NC                          \-                   121/386   [rs9851685](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=9851685)
  c.2276--128_2276--127insT   \-                  Hetero        NA               \-                         NC                          \-                   1/386     this study
  c.2808G\>A                  p.(A936=)           Hetero/homo   NA               \-                         NC                          \-                   35/386    [rs117475774](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=117475774)
  c.2796C\>T                  p.(R932=)           Hetero        NA               \-                         NC                          \-                   8/386     [rs35540805](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=35540805)
  c.2819--4A\>G               \-                  Hetero        NA               \-                         NC                          \-                   2/386     [rs184273607](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=184273607)
  c.2883+2T\>C                \-                  Hetero        NA               \-                         NC                          \-                   1/386     this study

Abbreviations: Hetero, Heterozygous; Homo, Homozygous; B, benign; NC, not changed; T, tolerated; NA, not analyzed.

Optic atrophy 1 compound heterozygous mutations
-----------------------------------------------

A 4-year-old boy harbored two *OPA1* mutations, c.190_194del (p.S64fs) and c.1129G\>A (p.V377I). Segregation analysis demonstrated that the deletion was inherited from his father and the missense mutation from his mother ([Figure 2](#f2){ref-type="fig"}), indicating compound heterozygosity. The boy was observed suffering from poor vision as early as 2 years of age. Fundus examination revealed temporal disc pallor in both eyes when he was 4 years old. Retinal nerve fiber layer (RNFL) thinning was confirmed with optical coherence tomography (OCT). Pattern visual-evoked potential (PVEP) showed prolonged latencies and diminished amplitudes in both eyes. In contrast, his father presented a much milder phenotype: His best-corrected visual acuity was 20/30 (Snellen) for both eyes, and his refraction was −1.50 sph for the right eye and −3.50 sph for the left eye. Fundus examination of the father showed bilateral disc pallor similar to his son while OCT and PVEP tests revealed milder abnormalities compared with the son. The mother had normal visual acuity of 20/20 (Snellen) for both eyes without any detectable abnormalities on fundus observation, OCT scan, and PVEP recordings. No extraocular neurologic sign presented in the proband and his parents ([Table 4](#t4){ref-type="table"}).

![Segregation analysis of Optic Atrophy 1 mutations in three families with dominant optic atrophy. Circles represent women, and squares represent men. Two circles and a square filled in black indicate probands with suspected hereditary optic atrophy. Circles and squares filled with lines show carriers with Optic Atrophy 1 (*OPA1*) variants. Proband le2028 is compound heterozygous for *OPA1* mutations. The father has a c.190_194del mutation in exon 2, and the mother has a c.1129G\>A in exon 11. Both mutations transmitted to their son. Proband le1432 inherited a c.2389A\>G mutation from her father. Proband le2062 inherited a c.2708_2711del mutation from her mother. The mutational sites are indicated with an asterisk, and amino acid codes are depicted with a line.](mv-v19-292-f2){#f2}

###### Clinical characteristics of the patients with *OPA1* mutations.

  Patient ID   OPA1 mutations                   Sex   Age (year) at   Inheri- tance   BCVA   Optic   VEP    RNFL thinning   Scotoma                           
  ------------ -------------------------------- ----- --------------- --------------- ------ ------- ------ --------------- --------- ----- ----- ----- ----- -----
  le1608       c.49_50insGG                     M     12              9               Spo    0.3     0.2    Yes             Yes       No    NA    NA    NA    NA
  le2028       c.\[190_194del\]; \[1129G\>A\]   M     4               2               Fam    0.05    0.05   Yes             Yes       Yes   Yes   Yes   NA    NA
  le2028F      c.190_194del                     M     39              NA              Fam    0.6     0.7    Yes             Yes       No    Yes   Yes   No    No
  le2028M      c.1129G\>A                       F     33              NA              Fam    1.5     1.5    No              No        No    No    No    No    No
  le2146       c.985--1G\>A                     M     16              6               Fam    0.2     0.4    Yes             Yes       Yes   NA    NA    Yes   Yes
  le1524       c.989C\>G                        M     17              17              Fam    0.3     0.15   Yes             NA        NA    NA    NA    Yes   Yes
  le1656       c.991_992del                     M     8               7               Spo    0.1     0.1    Yes             Yes       Yes   NA    NA    Yes   Yes
  le1599       c.2119G\>T                       F     24              14              Spo    0.3     0.3    Yes             Yes       Yes   NA    NA    Yes   Yes
  le1432       c.2389A\>T                       F     13              10              Spo    0.4     0.2    Yes             NA        NA    Yes   Yes   Yes   Yes
  le1432F      c.2389A\>T                       M     41              NA              Spo    0.7     0.7    Yes             NA        NA    Yes   Yes   NA    NA
  le1601       c.2470C\>T                       F     35              35\*            Spo    0.3     0.2    Yes             NA        NA    NA    NA    NA    NA
  le1574       c.2614--2A\>G                    M     24              24\*            Spo    0.2     0.3    Yes             NA        NA    NA    NA    NA    NA
  le1434       c.2708_2711del                   M     6               3               Spo    0.2     0.4    Yes             Yes       Yes   Yes   Yes   NA    NA
  le1411       c.2708_2711del                   M     9               6               Spo    0.2     0.2    Yes             NA        NA    NA    NA    NA    NA
  le2062       c.2708_2711del                   F     17              12              Spo    0.4     0.4    Yes             Yes       Yes   NA    NA    No    No
  le2062M      c.2708_2711del                   F     49              NA              Spo    0.7     0.7    Yes             NA        NA    Yes   Yes   NA    NA

Analysis of the family members in two sporadic cases (le1432 and le2062) demonstrated that one parent in each of the two families had the *OPA1* mutation and mild phenotype of optic atrophy. The asterisk indicates the time when obvious visual deterioration occurred after taking antituberculosis medicine. Abbreviations: Fam, family; Spo, sporadic; BCVA, best-corrected visual acuity; RNFL, retinal nerve fiber layer; M, male; F, female; OD, right eye; OS, left eye; NA, not available.

Clinical characteristics of optic atrophy 1-positive patients
-------------------------------------------------------------

All probands with *OPA1* mutations had clinical symptoms and signs of DOA ([Table 4](#t4){ref-type="table"}). The disease occurred insidiously in most probands, with reduced visual acuity noticed at about 12 years old (12±9.5 years; ranging between 2 and 35 years). The mean age for the probands' first visit to the eye clinic was about 15 years (15±8.8 years; ranging from 4 to 35 years). Interestingly, two probands (le1574 and le1601) experienced significant visual deterioration after taking antituberculosis medicine. Additional segregation analysis of the mutations was performed in two sporadic cases, i.e., le1432 and le2062, through contact tracing of the *OPA1*-positive probands ([Figure 2](#f2){ref-type="fig"}). The two patients had no siblings, but their parents were available for further analysis. All four parents were farmers and were visually asymptomatic by self-report. However, the father of le1432 and the mother of le2062 harbored an *OPA1* mutation. Ophthalmic examination of the two "healthy carriers" demonstrated mild phenotype of optic atrophy: mild reduced visual acuity, attenuated retinal vessels, temporal disc pallor, and thinning RNFL on the OCT scan ([Table 4](#t4){ref-type="table"}).

Discussion
==========

DOA and LHON are the most common hereditary optic neuropathies in the general population \[[@r4],[@r33],[@r34]\], with similar prevalence in Caucasians \[[@r1],[@r9]\]. Ferre et al. reported identification of genetic defects in 440 of 980 cases (45%) with suspected hereditary optic neuropathy, including *OPA1* mutations in 295 (30%) patients, mtDNA mutations in 131 (13%) patients, and *OPA3* mutations in 14 (1.4%) patients \[[@r21]\]. These results suggest that *OPA1* mutations are the most common cause for patients with suspected hereditary optic atrophy. However, there is no molecular epidemiological study for DOA in Chinese populations even though there are large case series of such studies for Chinese patients with LHON \[[@r28]\]. It is unclear whether DOA is rare in Chinese or may not be easily recognized in clinics compared to LHON. Clinically, it may be difficult to distinguish DOA from LHON in many cases, especially in the atrophic phase \[[@r35],[@r36]\]. In our previous report of a molecular epidemiological analysis of 903 families with optic neuropathy, the three primary mutations (G11778A, T14484C, and G3460A) in mtDNA were identified in 346 families (38.3%) \[[@r28]\]. In this study, mutations in *OPA1* were detected in only 12 of the 193 families (6.2%). Since patients with one of the three primary mtDNA mutations (G11778A, T14484C, and G3460A) were not included in the cohort, the actual detection rate of *OPA1* mutations in Chinese patients with hereditary optic neuropathy should be even lower, indicating a significantly lower frequency of *OPA1* mutations (\<6.2%) and a comparatively higher frequency of mtDNA mutations (38%) in Chinese patients with suspected hereditary optic neuropathy compared with French Caucasians (30% for OPA1 and 13% for mtDNA) \[[@r21]\]. Lack of awareness of the mild phenotype of DOA may contribute to the low frequency of *OPA1*-related DOA in Chinese and relatively high frequency of *OPA1* mutations in sporadic cases, which is implied by the segregation analysis of mutations in the family of le1432 and le2062. A family history showing autosomal dominant inheritance is a key indicator leading to clinical diagnosis of DOA and genetic analysis of OPA1. For the probands from the 12 families with *OPA1* mutations identified in this study, however, most (9/12, 75%) were sporadic cases (nine out of 155 sporadic cases). Similar frequency of *OPA1* mutations in singleton cases was also mentioned in other studies \[[@r16],[@r21],[@r24],[@r37]\]. Since individuals who harbor *OPA1* mutations may have mild phenotypes that the individuals are unaware of, it is important to keep *OPA1* in mind for patients with suspected hereditary optic neuropathy without a family history and evaluate the family members of these singleton cases carefully. Moreover, such evaluation and genetic consultation to family members may be crucial since more severe phenotypes might be induced by toxic materials, such as alcohol, smoking, and some drugs, as seen in two patients who had taken medicine for tuberculosis in this study.

Although *OPA1* mutations contribute to the most (60%--70%) cases with DOA \[[@r19]\], the genetic diagnosis of DOA is still a challenge. *OPA1* mutations are spread over 30 exons \[[@r21]\]. In addition, about a quarter of the mutations are located in the intronic regions adjacent to exon-intron boundaries, which usually affect splicing \[[@r20]\]. Under this circumstance, a cost-effective method for identifying mutations responsible for DOA is of great value. Screening the most frequently mutated exons of OPA1 initially would be a feasible strategy. Although exons 27, 8, and 15 were suggested to be regions of mutation hot spots in a previous study by Ferre et al. \[[@r21]\], we are unable to suggest ethnic-specific mutation hot spots based on limited number of mutations identified in our cohort of Chinese patients. The c.2708_2711del mutation in exon 27 was present in approximately 27% of families in previous studies. The same mutation was found in three probands in our study, which accounts for 25% among the *OPA1*-positive cases, further confirming that it is a mutational hot spot \[[@r21],[@r24],[@r37]\]. Interestingly, three novel mutations, discovered in three unrelated patients, arose from a region less than 10 bp around the 5′ end of exon 10, which may imply another mutational hot spot. Thus far, this is the largest series of patients screened for *OPA1* in an Asian population. As our results provide evidence of ethnic variations in the mutation frequency of *OPA1*, analyzing causative genes and their exons in a systematic and population-specific fashion is necessary, especially in the context of genetic counseling for different ethnic groups.

To our knowledge, the patient with confirmed compound heterozygosity of *OPA1* mutations in our study is the fourth case reported so far \[[@r38],[@r39]\], which represents a rare event. All cases with compound heterozygous *OPA1* mutations reported thus far had more severe phenotypes than their parents with a single heterozygous *OPA1* mutation, which may suggest an additive effect \[[@r39]\]. Although the mother is a possible case of non-penetrance in optic atrophy, the c.1129G\>A (p.V377I) mutation is still likely to be pathogenic. First, the mutation is rare as it is not found in 384 control chromosomes or the Single Nucleotide Polymorphism database. Second, the mutation is located in an evolutionarily conserved region and is predicted to be probably damaging by PolyPhen-2. Third, the severity of the phenotype of the son could, at least partly, reflect the addictive effect of the mutation from his mother. However, it is not the only interpretation of this compound heterozygous case. A c.190_194del (p.S64fs) mutation was identified in the father, presumably causing premature termination. However, the phenotype of the father was much milder than the other probands with frameshift deletions or nonsense mutations in our study. This may suggest the existence of modifier alleles at other loci. If the son did not inherit the beneficial modifier alleles from his father, this could also result in the severity of the son's phenotype. The effect of modifier alleles may also explain the marked intrafamilial phenotypical heterozygosity between the probands and other mutation carriers, as shown in le1432 and le2062.

In summary, this study implies that the frequency of DOA is much lower than that of LHON in Chinese compared with other ethnic groups. Lack of awareness of the mild phenotype of DOA may contribute to the low frequency of *OPA1*-related DOA in Chinese. Further analysis of *OPA1* in individuals with mild visual impairment and temporal disc pallor may be helpful in disclosing the real frequency of DOA in Chinese. Routine clinical test of *OPA1* variations in such cases may also enhance the care of eyes through consultation and pretreatment, especially for individuals who are unaware of visual problems but harbor *OPA1* mutations.
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